J Diabetes
Bexagliflozin vs. dapagliflozin in type 2 diabetes: How do they stack up?
April 18, 2024
Bexagliflozin showed nearly identical effects and a similar safety profile to dapagliflozin when used in Chinese patients with T2DM on metformin.
Subjects (n = 406) in this multicenter trial were randomized to receive bexagliflozin (20 mg) or dapagliflozin (10 mg) plus metformin. Primary endpoint was noninferiority of bexagliflozin to dapagliflozin for the change in glycated hemoglobin (HbA1c) from baseline to week 24. Secondary endpoints included intergroup differences in fasting plasma glucose (FPG), 2-hr-postprandial glucose (PPG), body weight, and systolic blood pressure (SBP) from baseline to week 24. The trial also evaluated safety profiles of the two agents.
Study results:
- The model-adjusted mean change from baseline to week 24 HbA1c was -1.08% for bexagliflozin and -1.10% for dapagliflozin. The intergroup difference of 0.03% (95% confidence interval [CI] -0.14% to 0.19%) was below the prespecified margin of 0.4%, confirming noninferiority of bexagliflozin.
- Changes from baseline in FPG, PPG, body weight, and SBP were -1.95 mmol/L, -3.24 mmol/L, -2.52 kg, and -6.4 mm Hg in the bexagliflozin arm and -1.87 mmol/L, -3.07 mmol/L, -2.22 kg, and -6.3 mm Hg in the dapagliflozin arm.
- Rates of adverse events were 62.6% and 65.0%, and rates of serious adverse events were 4.4% and 3.5%, in the bexagliflozin and dapagliflozin arms, respectively.
epocrates Related Resources:
Source:
Xie L, et al. (2024, April 16). J Diabetes. Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled, phase 3 trial. https://pubmed.ncbi.nlm.nih.gov/38584148/
TRENDING THIS WEEK
